Demographic and Clinical Factors Associated With SARS-CoV-2 Anti-Nucleocapsid Antibody Response Among Previously Infected US Adults: The C4R Study

Despite the availability of effective vaccines and a recent decrease in annual deaths, COVID-19 remains a leading cause of death. Serological studies provide insights into host immunobiology of adaptive immune response to infection, which holds promise for identifying high-risk individuals for adverse COVID-19 outcomes. We investigated correlates of anti-nucleocapsid antibody responses following SARS-CoV-2 infection in a US population-based meta-cohort of adults participating in longstanding National Institutes of Health-funded cohort studies. Anti-nucleocapsid antibodies were measured from dried blood spots collected between February 2021 and February 2023. Among 1419 Collaborative Cohort of Cohorts for COVID-19 Research participants with prior SARS-CoV-2 infection, the mean age (standard deviation) was 65.8 (12.1), 61% were women, and 42.8% self-reported membership in a race/ethnicity minority group. The proportion of participants reactive to nucleocapsid peaked at 69% by 4 months after infection and waned to only 44% ≥12 months after infection. Higher anti-nucleocapsid antibody response was associated with older age, Hispanic or American Indian Alaskan Native (vs White) race/ethnicity, lower income, lower education, former smoking, and higher anti-spike antibody levels. Asian race (vs White) and vaccination (even after infection) were associated with lower nucleocapsid reactivity. Neither vaccine manufacturer nor common cardiometabolic comorbidities were not associated with anti-nucleocapsid response. These findings inform the underlying immunobiology of adaptive immune response to infection, as well as the potential utility of anti-nucleocapsid antibody response for clinical practice and COVID-19 serosurveillance.

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2025-02-28
DOI
https://doi.org/10.1093/ofid/ofaf123
Citations
2
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
2.79
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Demographic and Clinical Factors Associated With SARS-CoV-2 Anti-Nucleocapsid Antibody Response Among Previously Infected US Adults: The C4R Study

Jean M. Rock, John S. Kim, Rachel Bievenue, Rebekah Boyle et al.
2 citations
Open Forum Infectious Diseases
SARS-CoV-2 and COVID-19 Research
2.79
article

Demographic and Clinical Factors Associated With SARS-CoV-2 Anti-Nucleocapsid Antibody Response Among Previously Infected US Adults: The C4R Study

Jean M. Rock, John S. Kim, Rachel Bievenue, Rebekah Boyle, Elizabeth A. Regan, Ryan T. Demmer, Mitchell S.V. Elkind, Mary Cushman, Norrina B. Allen, Carmen R. Isasi, Alka M. Kanaya, Joel Henderson, Laura M. Raffield, Victor E. Ortega, Josef Coresh, Russell P. Tracy, Margaret F. Doyle, Barry J. Make, Elizabeth C. Oelsner, Christina Wu, Vanessa Xanthakis, Sally E. Wenzel, Pallavi Balte, Linda M. Styer, Prescott G. Woodruff, Taison D. Bell, Amber Pirzada, Russell Bowler, Shelley A. Cole, Namratha R. Kandula, Pamela J. Schreiner, Yifei Sun, Michaela Restivo Anderson, Virginia J. Howard, Nicholas John Mantis, David A. Schwartz, Joyce Lee
article en
2 citations

Abstract

Despite the availability of effective vaccines and a recent decrease in annual deaths, COVID-19 remains a leading cause of death. Serological studies provide insights into host immunobiology of adaptive immune response to infection, which holds promise for identifying high-risk individuals for adverse COVID-19 outcomes. We investigated correlates of anti-nucleocapsid antibody responses following SARS-CoV-2 infection in a US population-based meta-cohort of adults participating in longstanding National Institutes of Health-funded cohort studies. Anti-nucleocapsid antibodies were measured from dried blood spots collected between February 2021 and February 2023. Among 1419 Collaborative Cohort of Cohorts for COVID-19 Research participants with prior SARS-CoV-2 infection, the mean age (standard deviation) was 65.8 (12.1), 61% were women, and 42.8% self-reported membership in a race/ethnicity minority group. The proportion of participants reactive to nucleocapsid peaked at 69% by 4 months after infection and waned to only 44% ≥12 months after infection. Higher anti-nucleocapsid antibody response was associated with older age, Hispanic or American Indian Alaskan Native (vs White) race/ethnicity, lower income, lower education, former smoking, and higher anti-spike antibody levels. Asian race (vs White) and vaccination (even after infection) were associated with lower nucleocapsid reactivity. Neither vaccine manufacturer nor common cardiometabolic comorbidities were not associated with anti-nucleocapsid response. These findings inform the underlying immunobiology of adaptive immune response to infection, as well as the potential utility of anti-nucleocapsid antibody response for clinical practice and COVID-19 serosurveillance.

Open Forum Infectious DiseasesVol. 12(3)
Boston University (US), University of Vermont (US), Northwestern University (US), University of North Carolina at Chapel Hill (US), Boston Medical Center (US), Texas Biomedical Research Institute (US), San Francisco General Hospital (US), New York State Department of Health (US), Albert Einstein College of Medicine (US), University of Minnesota (US), Alabama Department of Public Health (US), Mayo Clinic (US), Wadsworth Center (US), Johns Hopkins University (US), Illinois College (US), University of Pittsburgh (US), University of California, San Francisco (US), Johns Hopkins Medicine (US), University of California System (US), National Jewish Health (US), University of Alabama at Birmingham (US), University of Illinois Chicago (US), Office of Minority Health (US), Mayo Clinic in Arizona (US), Mayo Clinic in Florida (US), University of Virginia (US), New York University (US), Columbia University (US), University of Pennsylvania (US), University of Colorado Denver (US)
Good health and well-being
Openalex Percentile: Top 12%
SARS-CoV-2 and COVID-19 Research
2.79
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.